Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. - Wikidata - awgldk - TriplyDB

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.

http://www.wikidata.org/entity/Q36562341

about

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Checkpoint inhibitors in hematological malignancies Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.The Evolution of Prognostic Factors in Multiple Myeloma.Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.Novel Immunotherapies for Multiple Myeloma.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis.Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

P2860

Q28554677-81E0E0DF-7EE9-441A-BB9B-B51743890D2B Q33638083-6C8F9B97-5ACB-40B6-94DF-9B6ACDF1A00B Q33651495-F8780535-1F8E-4C7C-9EF2-CC37D65EF94B Q33717146-8BF7E238-8021-44F4-8F81-32E2A6D45ACB Q37100703-EE2D3111-52A6-43C5-9440-99E5A0E08E1F Q37641801-786F645C-AE46-46CD-BD55-A00D467BD720 Q37656305-9E163301-C506-4B1F-9C18-39BC637C16EB Q37683483-3A196820-C747-4A4F-8DEA-F10B25B94A4D Q37718250-C42F5B14-AE82-49F2-B580-96E03D142AF2 Q38640444-4C6B006C-8696-496C-969F-8589322E300C Q39136762-8D3E30B9-4139-4047-879D-461D32558DDF Q39928926-693FF3FA-4FD8-41C6-96A8-0D1164B569AF Q41369044-F5160874-4972-4C27-98D4-535252667557 Q42700822-D42E9FB2-31A6-4B48-BB7C-243970C85114 Q47134535-3C25FB62-BE8F-461E-84BF-B98A33333E4F Q47773203-C9F9B73D-D24A-4FB2-A437-E89A900DA33E Q49309172-BDBD426E-73E0-4127-8815-C6E5D6345044 Q50930412-43C99D2F-C059-4303-86E4-C9A9CD177704 Q50993649-6ABC52D9-C435-4C02-8EDE-B698171CD0B0 Q52560940-1F4D67E4-76D2-4E96-9EEF-3F769402C4E3 Q52630284-3955F711-DDC1-4511-A99A-9AE85375EE83 Q55554723-D1E89AC6-62C1-4BB1-AAAB-62DECD208D67 Q58786066-CE94E0EF-DF3F-4B2D-A1C6-AA5475EF68C9 Q58790080-1178C23E-BF16-4EB5-9851-FE6D0AEF1710

P2860

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.

http://www.wikidata.org/entity/Q36562341

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Serum levels of soluble progra ...... survival in multiple myeloma.

@ast

Serum levels of soluble progra ...... survival in multiple myeloma.

@en

type

label

Serum levels of soluble progra ...... survival in multiple myeloma.

@ast

Serum levels of soluble progra ...... survival in multiple myeloma.

@en

prefLabel

Serum levels of soluble progra ...... survival in multiple myeloma.

@ast

Serum levels of soluble progra ...... survival in multiple myeloma.

@en

P1433

Q36562341-A969FC2F-51C1-4103-B706-7AE196072952

P1476

Q36562341-30E61CF5-84D6-4529-9D98-9A779AF0EDD6

P2093

Q36562341-0EA8B010-A35C-472B-8569-4807249A506B

Q36562341-35A2477D-E7F4-4555-B316-EF981B5B993E

Q36562341-3CEF2036-D96F-4CA2-A3BD-DF25A98B4E2C

Q36562341-435829C2-B6EE-49F1-A13E-B3F1BBFD1235

Q36562341-570A89EB-FA1E-4008-9822-3F63270BE61B

Q36562341-6CE3F0F5-8E80-4AAC-8D3E-FD7738A7F792

Q36562341-76AE8CEB-3C62-4F26-A954-D8FC16B55250

Q36562341-B5A3067A-3CEF-4C81-A9C5-664E4EE26D2A

P2860

Q36562341-0443A4BA-BFE8-4BD3-A961-C1D752DEB5D8

Q36562341-09BD1377-AC1B-4124-92DA-CBEFBAD099EF

Q36562341-0A79E6C4-9925-4207-B644-7E3F4E50D2EC

Q36562341-15BF5E7A-B262-434B-8163-15893EF248E8

Q36562341-17BC6FE4-CF20-4063-8452-8BB534D96CCE

Q36562341-1EE28441-9238-43EF-9776-D07AB9E64B6B

Q36562341-2B988C84-CCC4-4F56-A92E-E0550C0E2147

Q36562341-2EB60DEB-1139-438E-B218-43BA1B3DB2AB

Q36562341-31501663-87CD-410B-9E88-5B0143471B30

Q36562341-4BE66AE2-B749-41C4-9C2C-4587EEF1DC1D

P304

Q36562341-7ED2E4D2-C4D8-4B2E-B50D-A1A8C68DBDFB

P31

Q36562341-F0318B21-031B-40BF-AA6F-986ABA50F67D

P356

Q36562341-CFC0E0AC-1CC8-496D-9F99-22A75D071473

P407

Q36562341-51093203-6B8F-413B-94AA-87CE017C95D3

P433

Q36562341-0929DE28-76E7-43E6-A1E7-16E9211730D6

P478

Q36562341-4A6950DB-1FDD-4E3E-AC04-5BC79304362E

P577

Q36562341-C3373A8F-3B68-41EF-BAED-6EEB713D0D85

P5875

Q36562341-E9BBB251-1BCE-4079-B86C-0D8B5D40F999

P698

Q36562341-029B74D0-AA85-4AC0-9CBB-33F073DC2818

P932

Q36562341-62601410-A024-4C48-ACC3-CDFF8CB6FF30

P356

ONCOTARGET.5682

P1433

P1476

Serum levels of soluble progra ...... survival in multiple myeloma.

@en

P2093

Hao Chen

http://www.w3.org/2001/XMLSchema#string

Hua Wang

http://www.w3.org/2001/XMLSchema#string

Liang Wang

http://www.w3.org/2001/XMLSchema#string

Qi-Rong Geng

http://www.w3.org/2001/XMLSchema#string

Wei-da Wang

http://www.w3.org/2001/XMLSchema#string

Xiao-Qin Chen

http://www.w3.org/2001/XMLSchema#string

Yue Lu

http://www.w3.org/2001/XMLSchema#string

Zhong-Jun Xia

http://www.w3.org/2001/XMLSchema#string

P2860

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

PD-1 and its ligands in tolerance and immunity

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

International uniform response criteria for multiple myeloma.

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.

The roles of the new negative T cell costimulatory pathways in regulating autoimmunity.

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

P304

41228-41236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.5682

http://www.w3.org/2001/XMLSchema#string

P407

P433

38

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283446354

http://www.w3.org/2001/XMLSchema#string

P698

26515600

http://www.w3.org/2001/XMLSchema#string

P932

4747402

http://www.w3.org/2001/XMLSchema#string